TRAP1 Activation Could Correct the Lysosomal Storage Disorders and Bring Cholesterol Levels Back to Normal

Lysosomal storage disorders (LSDs), a class of fatal inherited neurodegenerative diseases, have been successfully reversed in patient cells and animals by researchers at the National Center for Advancing Translational Sciences. The results were published in iScience.

Understanding Spark Lightning Hand
Understanding Spark Lightning Hand Gerd Altmann/Pixabay

What are Lysosomal Storage Diseases?

According to StatPearls, Lysosomal storage diseases (LSDs) are inborn metabolic errors characterized by the excessive accumulation of substrates in various organ cells due to lysosome dysfunction. They contribute significantly to morbidity and mortality by causing malfunctions in the organs where they accumulate.

Substances that Triggered TRAP1

Dr. Ioannou and his associates created a technique to gauge a substance's impact on Niemann-Pick type C1. According to the Genetic Testing Registry, it is a slowly progressing lysosomal condition with primarily age-dependent symptoms. Although cognitive impairment may initially be modest, it soon becomes clear that affected people have progressive dementia.

They discovered that substances that triggered TRAP1 restored appropriate mitochondrial function and began recycling lysosomes, aiding in the reduction of lipids in lysosomes and cells. The best-performing compounds were refined chemically and put through additional testing by the researchers.

In this study, the researchers focused on the substances ML405 and 1685.

The research aimed to identify the protein targets of ML405/85 that would help to understand the drug's mode of action using drug affinity responsive target stability (DARTS). The idea behind this technique is that a protein coupled to a small molecule compound will show modest variations in its proteolytic profile, which can then be used for quantitative proteomic analysis to be discovered.

The researchers performed restricted proteolysis of the protein extracts after treating the cells with ML405, 1685, or vehicle, followed by tandem mass spectrometry. As anticipated, 1,016 proteins had identical peptide profiles across the three populations in the three samples (DMSO-, ML405-, and 1685-treated).

They concentrated on the 69 proteins whose profiles differed between the samples treated with the drug and those treated with the vehicle to identify possible targets. It's interesting to note that three candidates-ERP29, HYOU1, and TRAP1-are proteins from the heat shock family (HSP).

The researchers found that the expression of the predominantly mitochondrial TNF receptor-associated protein 1 (TRAP1) consistently and dramatically reduced lipid storage in human NPC3 cells and mouse NPC1 cells.

Cross-talk Between Mitochondria and Lysosomes

The researchers found that TRAP1 initiated crosstalk between mitochondria and lysosomes to restore the internal cellular balance. The researchers found it surprising that activating TRAP1 triggers a cascade that results in the restoration of regular lysosomal function in lysosomal storage diseases. Each lysosomal disease's underlying genetic defect is still present, but the crosstalk was able to bypass the genetic effect.

The researchers demonstrated that improving TRAP1 activity in cells from individuals with LSD Niemann-Pick disease type C1 could treat the lipid storage disorder and return cholesterol levels to normal.

Additionally, improving TRAP1 activity reversed the lipid storage in patient cells from different LSDs such as Fabry, Farber, and Wolman illnesses.


Further Studies to Implement

According to the researchers, the findings may have repercussions for other neurodegenerative illnesses with comparable underlying causes, like Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's.

To develop potential therapeutic therapies, scientists need to know more about how the chemicals might reverse some elements of lysosomal storage diseases. They also want to continue creating these compounds and researching the outcomes in various animal models, including how well they can cure more common neurological diseases like Alzheimer's and Parkinson's.


Check out more news and information on Medicine and Health in Science Times.

Join the Discussion

Recommended Stories

Real Time Analytics